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Abstract
Background: More than 120 000 people are diagnosed annually with bladder cancer in
the 28 countries of the European Union (EU). With>40 000 people dying of it each year,
it is the sixth leading cause of cancer. However, to date, no systematic cost-of-illness
study has assessed the economic impact of bladder cancer in the EU.
Objective: To estimate the annual economic costs of bladder cancer in the EU for 2012.
Design, setting, and participants: Country-speciﬁc cancer cost data were estimated
using aggregate data on morbidity, mortality, and health care resource use, obtained
from numerous international and national sources.
Outcome measurements and statistical analysis: Health care costs were estimated from
expendituresonprimary, outpatient, emergency, and inpatient care, aswell asmedications.
Costs of unpaid care and lost earnings due to morbidity and early death were estimated.
Results and limitations: Bladder cancer cost the EUs4.9 billion in 2012,with health care
accounting for s2.9 billion (59%) and representing 5% of total health care cancer costs.
Bladder cancer accounted for 3% of all cancer costs in the EU (s143 billion) in 2012 and
represented an annual health care cost ofs57 per 10 EU citizens, with costs varying>10
times between the country with the lowest cost, Bulgaria (s8 for every 10 citizens), and
highest cost, Luxembourg (s93). Productivity losses and informal care represented 23%
and 18% of bladder cancer costs, respectively. The quality and availability of comparable
cancer-related data across the EU need further improvement.
Conclusions: Our results add to essential public health and policy intelligence for
delivering affordable bladder cancer care systems and prioritising the allocation of
public research funds.
Patient summary: We looked at the economic costs of bladder cancer across the
European Union (EU). We found bladder cancer to cost s4.9 billion in 2012, with health
care accounting for s2.9 billion. Our study provides data that can be used to inform
affordable cancer care in the EU.
# 2015 European Association of Urology. Published by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).. Health Economics Research Centre, Nufﬁeld Department of Population
ford, Oxford OX37LF, UK. Tel. +44 1865 289 264.
E-mail address: ramon.luengo-fernandez@dph.ox.ac.uk (R. Luengo-Fernandez).* Corresponding author
Health, University of Ox1. Introduction
Cancer is a major health problem in the European Union
(EU). In 2009 it cost the health care systems of the
27 countries in the EU s51 billion, representing 4% of totalhttp://dx.doi.org/10.1016/j.eururo.2015.10.024
0302-2838/# 2015 European Association of Urology. Published by Elsevier
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).health care expenditures [1]. Including the burden associ-
ated with lost earnings, both from early mortality and
absence fromwork, and the costs of informal care, whereby
relatives and/or friends provided unpaid care for people
with cancer, the costs increased to s126 billion.B.V. This is an open access article under the CC
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quantified the costs for breast, colorectal, lung, and prostate
cancer, it did not evaluate how much of total cancer costs
could be attributed to bladder cancer. Bladder cancer is the
sixth leading cause of cancer in the EU [2], with
124 000 people diagnosed and >40 000 people dying from
the disease each year. By 2030 the annual incidence is
projected to increase to 219 000, two-fifths of this due to
the ageing of the European population [2]. Planning urologic
care systems across Europe requires not only good
epidemiology but also investment and cost-effective treat-
ments and pathways. Critical to these calculations is the
macroeconomic impact of bladder cancer.
Theaimof this study is to evaluate the economicburdenof
bladder cancer across the28countries thatmadeup theEU in
2012.We includedhealth care andnon–health care costs and
also updated the economic burden of all cancers for 2012.
2. Methods
Cancer was deﬁned by the World Health Organisation International
Classiﬁcation of Diseases, 10th revision, as codes C00–C97, and bladder
cancer was deﬁned as C67. For all countries we used the same
methodological framework to obtain data and value cancer-related
resource use [1,3,4]. Anannual time framewasadopted,whereby resource
use attributable to cancer and bladder cancer within themost recent year
forwhich datawere available weremeasured, regardless of disease onset.
Resource use was valued by applying country-speciﬁc unit costs. Costs
were converted to 2012prices [5], andnational currencieswere converted
to euros (s) using 2012 exchange rates. To allow comparisons between
countries, we also adjusted for cost of living using the purchasing power
parity (PPP) method [6]. This method measures the price of the same
bundle of goods in different countries and allows comparisons of costs
adjusted for differences in the cost of living between countries.
International andnational sourceswere consulted for country-speciﬁc
aggregatedata (seeSupplement1 formoredetail).Wealsoconsultedpeer-
reviewed published studies or national reports from governmental or
professional bodies. If no datawere found, extrapolationswere performed
from similar countries (eg, similar health care expenditure per person, life
expectancy, and geographic location).
2.1. Health care expenditure
Cancer health care service includedprimary care, accident andemergency
(A&E) care, hospital inpatient care, outpatient care, and medications
(see Supplement 1 for methodology, data sources, and the quality of each
data estimate).Other typesof activities relating to thepreventionof cancer
such as health education in community-based settings were not included
because of the difﬁculties in identifying activity levels.
Country-speciﬁc pharmaceutical expenditures on cancer for
2009 were obtained. This consisted of sales of antineoplastic agents
and endocrine treatment (Anatomical Therapeutic Chemical codes L1
and L2) [1]. Expenditures for 2009 were updated to 2012 by assuming a
4.6% annual growth in cancer-related pharmaceutical expenditures
[7]. Due to the absence of EU-level data on cancer-related pharmaceuti-
cal expenditures due to bladder cancer, this proportion (4%) was
obtained from reports from Germany (2%) and the Netherlands (6%) and
applied to the remaining countries [8,9].
2.2. Informal care costs
Informal care costs were equivalent to the opportunity cost of unpaid
care, that is, the time (work and/or leisure) that caregivers forgo, valuedin monetary terms, to provide unpaid care for relatives with cancer. We
used country-speciﬁc data from the International Agency for Research
on Cancer (IARC) [2] to estimate the number of people with cancer and
bladder cancer and data from the Survey of Health, Ageing and
Retirement in Europe [10] to assess the hours of informal care needed
by cancer and bladder cancer patients (see Supplement 1).
2.3. Productivity losses
Productivity costs included the foregone earnings related to cancer-
attributable mortality and morbidity. For all countries we assumed an
initial working age of 15 yr. Age- and gender-speciﬁc deaths due to
cancer and bladder cancer were obtained for all countries from Eurostat
[11]. The potential working-years lost was estimated as the difference
between the age at death andmaximum age of retirement (whichwe set
at 79 yr). However, this would overestimate the total working-years lost
because not everyone will be economically active (ie, either working or
actively searching for work) or employed. Therefore, age- and gender-
speciﬁcunemploymentandactivity rates for eachof the 28countrieswere
applied to the potential foregone earnings due to premature mortality
[12]. The total number of working-years lost was then multiplied by
gender-speciﬁc average annual earnings [13]. Future earnings lost due to
mortality were discounted to present values using a 3.5% annual rate (ie,
the value society attaches to present as opposed to future costs).
Costs due to cancer-related morbidity comprised both the costs
associated with individuals declared incapacitated or disabled because
of cancer (permanent absence) and the costs due to individuals taking
sickness leave for a deﬁned time period (temporary absence) (see
Supplement 1). Costs were estimated by multiplying the total working
time lost due to cancer by mean earnings [12]. We used the friction
period approach because absent workers are likely to be replaced,
whereby costs for temporary and permanent absences were counted
only during the time taken to replace a worker (ﬁrst 90 d of work
absence).
2.4. Noneconomic burden
We obtained noneconomic measures of burden of cancer and bladder
cancer including number of deaths [11], incident disease cases [2],
prevalent disease cases (5 yr) [2], and disability-adjusted life years
(DALYs) lost. The rate, per 100 000 in the population, of DALYs lost for
cancer and bladder cancer was obtained for 2010 [14] and applied to
2012 population estimates [15].
2.5. Statistical analysis
We explored variations between countries in cancer-related health care
costs per capita using ordinary least squares (OLS) univariate regression
analyses conditional on national income (per capita), health care
expenditure (per capita), cancer incidence (crude rate), cancer mortality
(crude rate), mortality-to-incidence ratio (MIR), proportion of the
population who smoke, and cancer-speciﬁc DALYs (rate per 100 000).
An explanatory variable was signiﬁcant if its p value was <0.05. All
regressionanalyseswereperformedusingStatasoftwarev.12.1 (StataCorp,
College Station, TX, USA).
2.6. Sensitivity analysis
We estimated the effects on the total costs of bladder cancer of changes
in (1) health care resource use (all categories) and earnings (male and
female) across all countries, (2) proportion of cancer-related pharma-
ceutical expenditure due to bladder cancer (2% and 6%), (3) discounting
rate for productivity losses due to early mortality, and (4) no friction
period for costs due to cancer-related morbidity.
Table 1 – Noneconomic burden of cancers and bladder cancer
Country Deaths Incidence Prevalence, 5-yr data DALYs
Cancer Bladder cancer Cancer Bladder cancer Cancer Bladder cancer Cancer Bladder cancer
Austria 19 757 490 40 973 2159 114 793 7492 363 264 7811
Belgium 27 367 926 65 056 4348 192 018 14 220 554 321 12 670
Bulgaria 16 562 485 31 884 1662 75 554 4958 375 315 9496
Croatia 13 481 366 22 776 1053 61 969 3709 243 436 5362
Cyprus 1110 45 3417 227 10 420 803 27 652 734
Czech Republic 27 834 767 57 461 2462 145 631 8192 584 071 14 014
Denmark 14 886 492 35 984 1781 92 520 5607 300 846 9146
Estonia 3550 106 6095 209 14 791 607 59 171 1374
Finland 11 579 252 28 300 1093 83 641 3781 214 365 4040
France 155 331 5112 370 228 11 166 1 121 491 34 160 3 280 323 85 854
Germany 218 889 5516 491 825 28 403 1 396 766 100 676 4 237 296 105 824
Greece 27 159 1031 40 794 2777 101 880 9673 506 209 18 542
Hungary 32 460 904 50 286 2689 113 182 8057 656 401 14 103
Ireland 8094 188 20 655 666 54 920 2106 161 838 2979
Italy 167 251 5701 353 184 18 281 1 012 541 65 153 2 985 331 94 377
Latvia 6039 200 10 304 425 24 462 1233 101 110 2574
Lithuania 8110 248 14 462 569 34 785 1647 143 397 3163
Luxembourg 1018 42 2475 96 8264 540 22 329 469
Malta 840 33 1893 131 5207 492 16 748 463
Netherlands 42 359 1228 93 015 2999 267 924 10 296 835 530 21 415
Poland 92 610 3111 151 517 7960 350 227 23 566 1 969 546 55 534
Portugal 24 978 810 48 855 2874 134 272 8804 510 242 12 841
Romania 47 307 1391 78 316 3824 178 416 11 272 972 887 23 110
Slovakia 12 073 303 23 919 933 56 296 2666 269 049 4886
Slovenia 5834 184 11 407 463 28 909 1292 104 851 2460
Spain 103 307 4936 214 588 13 789 581 688 47 225 2 028 353 73 973
Sweden 21 646 684 50 262 2350 156 481 7885 387 014 9919
United Kingdom 157 581 4914 326 273 8776 827 126 27 410 2 913 926 69 591
TOTAL EU 1 269 012 40 465 2 646 204 124 165 7 246 174 413 522 24 824 821 666 726
DALY = disability-adjusted life year; EU = European Union.
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3.1. Noneconomic burden
In 2012 cancer was diagnosed in 2.6 million people;
124 000 of these were due to bladder cancer (5%;
Table 1). More than 7 million people were estimated to
be either living with or having survived cancer, with
410 000 (6%) due to bladder cancer. Approximately
1.3 million people died of cancer; 3% of these were due
to bladder cancer (Table 1). Furthermore, 25 million DALYs
were due to cancer, of which>660 000 were due to bladder
cancer (3%).
3.2. Economic burden of bladder cancer
Bladder cancer cost the EU s4.9 billion in 2012 (Table 2 and
Supplementary Table 5). The five most populous countries
(ie, France, Germany, Italy, Spain, and the United Kingdom)
accounted for s3.6 billion (73% of all costs).
Bladder cancer cost EU health care systems s2.9 billion
in 2012 (Table 2), representing 59% of the total economic
burden. Inpatient care was the major cost component,
accounting for 58% (s1.7 billion) of health care costs,
followed by expenditures on drugs at s568 million (20% of
total health care costs). Annual health care costs of bladder
cancer were equivalent to s57 per every 10 EU citizens(Fig. 1) but variedwidely between countries, with a 12-time
difference between the lowest (Bulgaria: s8 for every
10 citizens) and highest cost per capita (Luxembourg: s93
for every 10 citizens). Health care costs were s6942 per
prevalent case, but these also varied considerably between
countries, with a five-time difference between the lowest
(Latvia: s2257) and highest spender (France: s11 937),
after adjusting for price differentials (Supplementary Fig. 1).
The OLS regression showed a strong positive association
between bladder cancer health care costs (per capita and
per prevalent case) and national health care expenditures
(p < 0.01) and national income (p < 0.01). No significant
associations between bladder cancer health care costs
(per capita and per prevalence case) and incidence,
mortality, MIR, smoking rates, and DALYs were identified
(Supplementary [1_TD$DIFF] igures 3[2_TD$DIFF]–9).
Unpaid care accounted for>88 million hours with a cost
of s900 million (18% of total costs; Table 2). Approximately
34 000 working-years were lost due to mortality, which
were valued at s770 million (16% of total costs). We
estimated that 3 million working-days were lost in
2012 due to cancer-relatedmorbidity, which, when adjusted
using the friction period, accounted for s330 million
(7% of the total economic burden).
Sensitivity analysis showed that a 20% variation in health
care resource use had the biggest impact on total bladder
cancer costs (12% change), with the resulting total costs
Table 2 – Costs of bladder cancer (E thousands) in the European Union, by country, 2012
Country Health care costs Productivity losses Informal care costs Total costs
Primary
care
Outpatient
care
A&E Inpatient
care
Medications Total
health
care
Total cancer
health
expenditure, %
Mortality Morbidity Total Total cancer
cost, %
Austria 1617 2709 1105 34 680 15 784 55 895 4 13 126 9 976 12 153 91 151 3
Belgium 2453 4879 651 33 763 15 922 57 668 5 17 998 18 820 26 503 120 990 3
Bulgaria 416 493 70 2555 2003 5538 4 2776 1905 1567 11 785 3
Croatia 1053 588 2039 2110 3382 9172 4 4537 5382 2881 21 972 3
Cyprus 119 312 123 393 995 1941 6 1130 316 1196 4584 4
Czech Republic 2793 6836 1320 14 964 9213 35 126 6 7572 7503 6392 56 594 4
Denmark 301 898 264 11 789 9416 22 668 4 21 009 15 804 25 656 85 137 3
Estonia 272 496 237 1485 478 2967 4 1083 598 675 5323 3
Finland 1440 9020 1302 17 395 7202 36 360 4 6817 1 663 7557 52 397 3
France 10 062 15 951 1938 289 682 139 084 456 717 5 97 052 47 475 101 911 703 154 3
Germany 45 531 37 469 989 461 769 64 208 609 965 4 157 594 78 163 170 065 1 015 787 3
Greece 4317 9649 1909 34 199 13 250 63 323 6 10 594 4651 14 035 92 603 4
Hungary 1311 2031 338 7305 10 169 21 155 3 6561 1606 5671 34 994 3
Ireland 1350 1410 745 10 450 5828 19 782 3 6829 1474 4542 32 627 2
Italy 60 396 67 557 45 120 284 646 76 499 534 216 7 80 530 7671 192 078 814 495 5
Latvia 312 722 63 1029 511 2638 4 1382 494 1155 5669 3
Lithuania 480 470 138 1184 399 2671 4 1875 685 1065 6296 3
Luxembourg 285 516 39 2877 1183 4900 5 1612 884 1425 8821 4
Malta 27 44 16 411 555 1053 5 405 45 511 2012 4
Netherlands 9043 13 858 1206 93 303 16 422 133 832 5 50 550 16 564 28 717 229 663 3
Poland 9042 28 015 1034 30 337 11 977 80 405 6 33 293 20 825 22 216 156 740 4
Portugal 4567 7541 1877 7323 11 342 32 649 5 19 678 4738 13 915 70 980 3
Romania 854 2834 127 6188 8939 18 942 4 11 885 4849 5560 41 237 3
Slovakia 2005 4874 245 3805 5129 16 058 5 1909 2663 2050 22 680 3
Slovenia 217 459 297 4159 2151 7283 4 2709 3508 2514 16 014 3
Spain 43 539 25 406 14 636 131 669 69 662 284 912 5 65 856 19 621 128 151 498 540 4
Sweden 4665 15 309 3618 30 240 12 585 66 416 5 17 313 21 533 18 404 123 666 4
United Kingdom 3793 71 664 4192 153 029 53 702 286 380 5 126 204 29 754 101 291 543 630 3
TOTAL EU 212 258 332 009 85 637 1 672 739 567 991 2 870 634 5 769 879 329 170 899 857 4 869 542 3
A&E = accident and emergency; EU = European Union.
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Fig. 1 – Total health care costs (E), not adjusted for price differentials, of bladder cancer by health care service category (A) per 10 in the population,
2012, and (B) per prevalent bladder cancer case.
E U RO P E AN URO LOG Y 6 9 ( 2 0 1 6 ) 4 3 8 – 4 4 7442varying between s4.3 and s5.4 billion (Supplementary Fig.
10). The 20% variation in earnings resulted in an 8% change
on total bladder cancer costs, with these varying between
s4.5 and s5.3 billion.3.3. Bladder cancer as a proportion of total cancer costs
The total cancer costs in the EU were estimated at
s143 billion in 2012 (Table 3 and Supplementary Table 8),
Table 3 – Costs of cancer (E thousands) in the European Union, by country, 2012
Country Health care costs Productivity losses Informal care costs Total costs
Primary
care
Outpatient
care
A&E Inpatient
care
Medications Total
health
care
Total
health
expenditure, %
Mortality Morbidity Total GDP, %
Austria 35 888 60 134 24 517 842 330 392 932 1 355 801 4 1 062 446 369 546 357 421 3 145 215 1.02
Belgium 35 515 70 632 9418 702 639 396 369 1 214 574 3 1 263 559 783 295 627 126 3 888 554 1.03
Bulgaria 9240 10 964 1565 56 170 49 861 127 799 5 159 855 41 868 42 949 372 472 0.93
Croatia 24 875 13 896 48 201 65 496 84 196 236 665 8 273 979 231 915 87 481 830 040 1.91
Cyprus 1068 2808 765 4540 24 773 33 955 3 56 585 6601 23 941 121 082 0.68
Czech Republic 32 018 78 366 15 129 278 463 229 354 633 331 6 523 448 236 458 181 275 1 574 512 1.03
Denmark 6899 56 498 7855 299 211 234 398 604 861 2 1 167 468 396 098 737 586 2 906 014 1.18
Estonia 7988 14 579 6973 31 623 11 905 73 067 7 64 522 39 182 21 156 197 928 1.14
Finland 38 094 190 986 27 561 535 402 179 297 971 340 6 640 870 106 867 314 278 2 033 355 1.06
France 118 410 187 718 22 806 4 681 469 3 462 372 8 472 775 4 6 221 407 2 796 025 3 040 203 20 530 410 1.01
Germany 1 316 014 1 082 986 22 925 9 824 295 2 732 580 14 978 799 5 12 802 215 2 250 307 4 734 815 34 766 136 1.30
Greece 58 052 129 744 25 670 534 413 329 836 1 077 715 6 622 867 72 683 318 728 2 091 994 1.08
Hungary 38 753 60 049 10 006 251 296 253 159 613 264 8 460 174 72 588 168 948 1 314 973 1.36
Ireland 32 269 33 694 17 804 400 357 145 071 629 196 4 571 817 102 212 175 213 1 478 437 0.90
Italy 537 037 600 712 401 205 3 870 315 1 904 371 7 313 639 5 5 081 057 169 699 4 820 340 17 384 735 1.11
Latvia 6436 14 880 1306 27 441 12 711 62 774 5 99 810 21 721 30 597 214 903 0.97
Lithuania 8963 8780 2581 31 449 9938 61 711 3 115 910 39 712 31 261 248 594 0.75
Luxembourg 4582 8293 627 59 746 29 439 102 687 4 60 723 41 319 30 120 234 849 0.55
Malta 817 1348 498 7714 9884 20 260 3 14 080 1165 11 140 46 646 0.68
Netherlands 126 000 193 079 16 798 2 174 600 288 905 2 799 382 4 2 781 602 557 599 912 671 7 051 254 1.18
Poland 101 656 314 960 11 630 513 845 298 155 1 240 246 5 1 597 574 533 564 561 867 3 933 251 1.03
Portugal 71 473 118 014 29 372 141 055 282 337 642 252 4 1 058 365 91 259 351 235 2 143 112 1.30
Romania 20 546 68 199 3134 158 524 222 534 472 937 9 803 769 119 766 152 038 1 548 509 1.18
Slovakia 34 599 84 097 4235 96 639 127 683 347 254 6 202 230 112 862 67 765 730 111 1.03
Slovenia 3952 8356 5400 91 949 53 555 163 212 5 154 566 126 916 73 538 518 232 1.47
Spain 864 251 504 313 290 529 2 141 670 1 734 181 5 534 944 6 3 205 636 534 071 2 373 813 11 648 464 1.13
Sweden 71 174 233 559 55 198 721 068 313 295 1 394 294 4 1 062 042 513 982 533 911 3 504 229 0.86
United Kingdom 194 945 1 377 068 56 558 3 313 326 1 336 878 6 278 775 3 8 095 221 1 386 307 3 130 825 18 891 128 0.98
TOTAL EU 3 801 513 5 528 713 1 120 266 31 857 045 15 149 973 57 457 509 5 50 223 799 11 755 588 23 912 240 143 349 138 1.11
A&E = accident and emergency; EU = European Union; GDP = gross domestic product.
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E U RO P E AN URO LOG Y 6 9 ( 2 0 1 6 ) 4 3 8 – 4 4 7444with bladder cancer accounting for 3%. InGreece, Italy,Malta,
and Spain, bladder cancer represented>4% of all total cancer
costs, whereas in Ireland, the country with the lowest
proportion,bladdercanceraccounted for approximately2%of
total costs.
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Fig. 2 – Total health care costs (E), not adjusted for price differentials, of canc
(B) per prevalent cancer case.The health care cost of cancer was s57 billion (Table 3),
with bladder cancer representing 5% of these costs. In Italy,
bladder cancer accounted for 7% of total cancer care costs,
whereas in Hungary and Ireland, it accounted for <3%.
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and adjusted for price differentials, respectively.
4. Discussion
We estimated the total costs of bladder cancer to be
s4.9 billion in 2012 across the EU. To our knowledge this is
the first study to provide estimates of the economic burden
of bladder cancer in the EU.
The annual health care expenditures due to bladder
cancer accounted for s57 per 10 EU citizens or s6942 per
prevalent case. The largest component of health care costs
was inpatient care (s1.7 billion [58%]) followed by the costs
of medicines (s0.6 billion [20%]). In the United States,
inpatient and outpatient costs of bladder cancer were
estimated at s3.2 billion in 2010 [16], which amounts to
twice the expenditure per 10 US citizens relative to the EU
(s97 PPP in the United States vs s45 in EU), after adjusting
for price differentials. A similar ratiowas foundwhen health
care costs were estimated per prevalent case, adjusting for
price differentials.
Some suggest [17] that this higher expenditure on
bladder cancermight explain the lower age-adjustedMIR in
the United States relative to the EU-28 countries as a whole
(0.21 vs 0.27 deaths per incident case in 2012). However,
when US mortality statistics are compared with European
countries with similarly high national incomes, these
differences disappear (eg, 0.15 in Germany, 0.34 in France,
and 0.23 deaths per incident case in Sweden) [2]. As a result,
some researchers have questioned the effectiveness of
higher US spending and suggested it is driven by higher
costs, unnecessary testing, and unproven medical proce-
dures [18]. The debate continues on whether higher
spending in the United States results in better cancer
outcomes [19] and how these can be best measured [20].
Large variations in bladder cancer health care costs were
also found between European countries, ranging from
s8 per 10 in the population in Latvia to s94 per 10 in
the population in Luxembourg. Although these differences
narrowed after adjusting for price differentials across
countries, important differences persisted. In our analysis,
the most important predictor of bladder-related health care
costs was per capita national income, which explained
higher unit costs in richer countries. For example, according
to Eurostat, average annual salaries in human health and
social work activities in Bulgaria were s4660 as opposed to
s35 434 in Sweden, which could explain the large
differences in the unit costs (eg, in Bulgaria a visit to a
specialist was found to cost s20 as opposed to >s300 in
Sweden).
However, even for countries with the same levels of
wealth, health care costs on bladder cancer varied widely.
For example, even though France and the United Kingdom
have similar levels of per capita gross domestic product,
France’s expenditure on bladder cancer–specific health care
was considerably higher than that of the United Kingdom.
Differences in health care expenditures due to bladder
cancer could be explained by health system configuration
(eg, the number of hospital bed days due to bladder cancerin Germany is substantially higher than in Sweden).
Substantial variations in pharmaceutical expenditure could
also be explained by a myriad of factors such as differences
in the introduction and use of new drugs, differences in the
prices paid for the same drugs, increased pharmaceutical
consumption in some countries; differences in the types of
medication consumed, different price setting and reim-
bursement mechanisms, or variations in clinical practice.
The patterns explaining the between-country differences in
bladder cancer expenditure should be researched further.
It is then important to identify the most efficient public
policy initiatives and health care systems capable of
achieving the best cancer outcomes so that benchmarks
can be set up across the EU member states. More research
is thus required on factors affecting access to treatment
and diagnosis and on biologic differences so that gender
differences in the incidence and mortality of bladder
cancer across the EU can be explained [21]. More EU
research is needed to address intelligence gaps concerning
the effectiveness and cost effectiveness of existing
management and surveillance technologies for bladder
cancer so that best practices can be based on robust
evidence [22].
Bladder cancer contributed to 3% of the total cancer costs
(s143 billion) in the EU in 2012. Luengo-Fernandez et al
(2013) [1] found that of the total economic cost of cancer in
2009, 44% was due to lung (15%), breast (12%), colorectal
(10%), and prostate cancers (7%). Of total health care cancer
costs in 2009, prostate cancer accounted for 11%, which is
considerably higher than that identified in this study for
bladder cancer (5%). However, according to the IARC, the
prevalence of prostate cancer is three times higher than that
of bladder cancer in the EU [2], suggesting that the health
care cost per prevalent cancer is higher for bladder than
prostate cancer. Using the same methodology and sources
as that used for the 2009 analysis, we estimated that the
cost per prevalent bladder cancer was s5621 in 2009 com-
pared with s4282 for prostate cancer. These findings are
supported by research in 2011 estimating health care costs
of bladder cancer per patient to be higher than prostate
cancer across all disease phases [16].
Cost-of-illness data describe the magnitude of public
health problems and allow comparisons across different
types of cancers, diseases, and countries. If performed
consistently over long periods of time, these types of
analyses will aid prioritising health care resources and
research funding towards diseases with the highest burden,
identify the largest components of costs (eg, inpatient
services), and provide valuable data to support economic
evaluations of health care technologies. They can also
provide evidence to assess whether at the population level,
cancer care policies, such as increases in pharmaceutical
expenditure, cost containment plans, and screening pro-
grammes, are translated into changes in cancer-specific
health care costs, which then in turn can be evaluated
against changes in outcome or non–health care cancer
costs. Hence such data can aid decisions about the
allocation of EU resources including service provision,
prevention strategies, and future research funding [23].
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s126 billion to s143 billion between 2009 and 2012 across
the EU-27 countries included in both analyses. According to
the IARC and Eurostat, cancer incidence and mortality
increased by 7% and 2%, respectively, in the same period.
This translated into the number ofworking-years lost due to
premature death increasing by 7.4 million years and days
lost due to absence from work increasing by 2.1 million.
These, together with changes in employment rates and
wages, led to an increase in lost earnings due to cancer-
related early death and absence from work of 18%
(s9.5 million). In terms of health care resource use, a
decrease was observed across most care categories. For
example, reported cancer-related inpatient days were 8%
(4.6 million days) lower in 2012 relative to 2009, without
any discernible increase in informal care costs (s23.2 billion
in 2009 vs s23.9 billion in 2012). However, the reduction in
cancer-related health care resource use was counter-
balanced by a significant rise in health care price inflation
and the introduction of newer andmore costly technologies
that resulted in an overall increase in health care costs of
s5.9 billion (12%).
This analysis has limitations. Despite the need to
improve and standardise disease and resource use data
across the EU [24], this remained largely unchanged
between 2009 and 2012. For example, we used >150
sources for this study, and with the exception of inpatient
days, national data were largely absent on the number of
primary care, outpatient care, and A&E visits due to cancers
and bladder cancer, requiring assumptions and extrapola-
tions to estimate these.Weprovide a grading systemhere for
each resource use and unit cost used regarding the quality of
the sources available (Supplementary Table 1 and 2). Due to
data availability, we did not consider other types of drugs,
such as antiemetic drugs. We also found a lack of detailed
prospective studies of cancer patients and national linked
databases ascertaining medication expenditure by type of
cancer and disease phase. As a result, the proportion of
country-specific cancer-related pharmaceutical expendi-
tures due to bladder cancer medication was ascertained
using estimates from two countries (Germany and the
Netherlands), which were then applied to the remaining
countries. However, a sensitivity analysis showedalternative
assumptions to result in changes of only 5% on total bladder
cancer costs. Finally, our absolute costs are likely to be an
underestimate. Some categories of health care costs, such as
public health activities and screening programmes, long-
term morbidities resulting from cancer treatments amongst
survivors, and care provided outside the health care system
(eg, hospices based outside hospitals), is not recorded for all
countries under study. However, the estimates of the
proportion of total cancer costs that were due to bladder
cancer are less likely to be affected because these were also
missing across all cancers.
5. Conclusions
Our study is the first to quantify the economic burden of
bladder cancer in the EU and its contribution to total cancercosts. Urologic services are key cancer-specific pathways in
EU countries, and bladder cancer makes up a significant
burdenon these systems.Webelieve that our studywill be of
particular interest to European policymakers implementing
affordable cancer care for all European citizens. Our study
updates and adds cost data to inform evidence-based policy
making.
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